Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan;75(1):124-137.
doi: 10.1053/j.ajkd.2019.04.031. Epub 2019 Jul 26.

ANCA-Associated Vasculitis: Core Curriculum 2020

Affiliations
Review

ANCA-Associated Vasculitis: Core Curriculum 2020

Duvuru Geetha et al. Am J Kidney Dis. 2020 Jan.

Abstract

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of disorders characterized by inflammation and destruction of small- and medium-sized blood vessels and the presence of circulating ANCA. Clinical disease phenotypes include granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, and renal-limited vasculitis. Serologic classification of AAV into proteinase 3-ANCA disease and myeloperoxidase-ANCA disease correlates with a number of disease characteristics. AAV has a predilection for the kidney, with >75% of patients having renal involvement characterized by rapidly progressive glomerulonephritis. The cause and pathogenesis of AAV are multifactorial and influenced by genetics, environmental factors, and responses of the innate and adaptive immune system. Randomized controlled trials in the past 2 decades have refined the therapy of AAV and transformed AAV from a fatal disease to a chronic illness with relapsing course and associated morbidity. This article in AJKD's Core Curriculum in Nephrology series provides a detailed review of the epidemiology, pathogenesis, diagnosis, and advances in the management of AAV.

Keywords: Vasculitis; anti-neutrophil cytoplasmic antibody (ANCA); autoantibody; complement; cyclophosphamide; glomerulonephritis; granulomatosis with polyangiitis (GPA); immunosuppression; microscopic polyangiitis (MPA); review; rituximab.

PubMed Disclaimer

MeSH terms